Crenessity (crinecerfont) — Classic Congenital Adrenal Hyperplasia (CAH) coverage criteria
Customize your policy alerts
Sign up for all Neighborhood Health Plan of Rhode Island policy alerts
Know when Neighborhood Health Plan of Rhode Island releases new policies or updates existing guidance.
Monitor payer policy activity
Policy governs prior authorization, dosing, quantity limits, and clinical criteria for Crenessity as adjunctive therapy to glucocorticoid replacement in pediatric (≥4 years) and adult patients with classic 21‑hydroxylase congenital adrenal hyperplasia (CAH). It affects prescribers, pharmacies, and prior authorization reviewers.
No material clinical or coverage changes in this revision.
Coverage Criteria for Crenessity (crinecerfont)
Initial Therapy
Covered when ALL of the following are met for initial therapy (authorization up to 6 months):
Initial auth duration: 6 months
Continuation Therapy / Reauthorization
Covered when ALL of the following are met for reauthorization (continued therapy):
Authorization duration for reauthorization: 6 months
Coverage is not provided for patients with diagnoses of other known forms of congenital adrenal hyperplasia (CAH), such as 11‑beta‑hydroxylase deficiency or 17‑alpha‑hydroxylase deficiency. Coverage is also excluded for patients with a history of bilateral adrenalectomy, hypopituitarism, or other conditions that require chronic glucocorticoid therapy.
Diagnostic Thresholds, Dosing, and Definitions
Authorization, Documentation, and Reauthorization Requirements
Initial authorization — 6 months
Initial prior authorization may be granted for up to 6 months when all clinical criteria for classic 21‑hydroxylase congenital adrenal hyperplasia (CAH) are met. Ensure patient is ≥ 4 years old, prescribed by or in consultation with an endocrinologist, and documentation confirming diagnosis and chronic supraphysiologic glucocorticoid requirement is provided.
- Initial authorization duration: 6 months
- Patient age ≥ 4 years required
- Prescriber: endocrinologist or in consultation with endocrinology
- Diagnosis confirmation: genetic test showing pathogenic CYP21A2 variants OR biochemical evidence (baseline morning 17‑OHP > 3,000 ng/dL by LC‑MS/MS OR cosyntropin stimulation 17‑OHP >10,000 ng/dL)
- Documentation of chronic supraphysiologic glucocorticoid regimen (dose thresholds by age in hydrocortisone equivalents)
- Crenessity prescribed in combination with glucocorticoid therapy
- Weight and dose documented and optimized per FDA guidance
- Oral solution requests for patients ≥20 kg require documented inability to swallow capsule
- No concomitant strong/moderate CYP3A4 inducers unless no alternative
Reauthorization requirements
Reauthorization may be granted for 6 months when documentation shows the patient has achieved or maintained a positive clinical response and all other continuation requirements are met.
- Documented positive clinical response (examples: reduction in total daily glucocorticoid dose from baseline, stabilization or decrease in androstenedione [A4] levels)
- Continued prescription by or in consultation with an endocrinologist
- Crenessity remains used in combination with glucocorticoid therapy
- Weight and requested dose documented and optimized per FDA‑approved guidelines
- Oral solution for patients ≥20 kg: documented medical rationale for inability to swallow capsule
- Documentation that Crenessity will not be taken with a strong/moderate CYP3A4 inducer, or that no appropriate alternative is available
Required documentation
Required documentation must be included in chart notes or the medical record to support both initial authorization and reauthorization.
- Genetic confirmation of pathogenic CYP21A2 variants OR laboratory evidence of 21‑hydroxylase deficiency (baseline morning 17‑OHP > 3,000 ng/dL by LC‑MS/MS OR cosyntropin stimulation 17‑OHP >10,000 ng/dL)
- Documentation of chronic supraphysiologic glucocorticoid therapy with dose (hydrocortisone equivalents) and duration (stable for ≥1 month)
- Current glucocorticoid regimen and evidence of clinical monitoring (e.g., A4 levels, dosing adjustments)
- Weight record and dose optimization consistent with FDA guidance
- For oral solution requests (≥20 kg): documented rationale for inability to swallow capsule
- Medication reconciliation showing no concomitant strong/moderate CYP3A4 inducers or documentation why alternatives are unavailable
Potential denial triggers
Denial or delay is likely if required clinical or administrative documentation is missing or if exclusionary clinical criteria are present.
- Missing documentation of classic 21‑hydroxylase CAH (no genetic confirmation or required 17‑OHP thresholds)
- Patient age < 4 years
- Medication not prescribed by or in consultation with an endocrinologist
- No documentation of chronic supraphysiologic glucocorticoid requirement or dose thresholds not met
- Request for Crenessity for non‑21‑hydroxylase CAH subtypes or excluded conditions (e.g., 11β‑hydroxylase deficiency, 17‑alpha‑hydroxylase deficiency, prior bilateral adrenalectomy, hypopituitarism)
- Concomitant use with a strong/moderate CYP3A4 inducer without documented rationale
Key Definitions and Diagnostic Thresholds
Background on Crenessity and Clinical Context
Crenessity (crinecerfont) is indicated as an adjunct to glucocorticoid replacement for patients with classic 21‑hydroxylase congenital adrenal hyperplasia (CAH) to help control excess androgen production while maintaining necessary adrenal replacement. The therapy is used in combination with glucocorticoids and aims to enable reduction of supraphysiologic glucocorticoid doses when clinically appropriate.
When considering Crenessity, ensure the patient meets diagnostic confirmation for classic CAH (genetic confirmation of pathogenic CYP21A2 variants or specified biochemical thresholds) and that the medication will be used concomitantly with glucocorticoid replacement. Concomitant use with strong or moderate CYP3A4 inducers should be avoided or justified by lack of alternatives.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.